A 12 Week, Double-Blind, Randomized, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension.

Trial Profile

A 12 Week, Double-Blind, Randomized, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Aliskiren; Aliskiren/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ACQUIRE
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2012 Results published in the Journal of Clinical Hypertension (Greenwich).
    • 22 Jan 2010 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top